Takeda Pharmaceutical (NYSE:TAK) Issues Quarterly Earnings Results

Takeda Pharmaceutical (NYSE:TAK) issued its quarterly earnings results on Thursday. The company reported $0.42 EPS for the quarter, beating the consensus estimate of $0.34 by $0.08, Zacks reports. Takeda Pharmaceutical had a return on equity of 10.00% and a net margin of 6.49%. Takeda Pharmaceutical updated its FY 2024 guidance to 3.330-3.330 EPS.

Takeda Pharmaceutical Stock Performance

Takeda Pharmaceutical stock traded up $0.45 during mid-day trading on Thursday, hitting $13.76. 1,444,837 shares of the company’s stock traded hands, compared to its average volume of 1,972,464. Takeda Pharmaceutical has a fifty-two week low of $12.57 and a fifty-two week high of $15.08. The stock has a market cap of $43.77 billion, a price-to-earnings ratio of 23.69, a P/E/G ratio of 0.24 and a beta of 0.51. The firm has a 50 day simple moving average of $13.30 and a two-hundred day simple moving average of $13.89. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.28 and a quick ratio of 0.77.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.